Lacosadel (Lacosamide)

Lacosamide enhances the slow inactivation of voltage‑gated sodium channels in neurons. This stabilises hyper‑excitable membranes, reduces repetitive firing, and limits the spread of seizure activity throughout the brain.

The specific dose of Lacosadel is determined by the prescribing clinician based on the patient’s age, weight, seizure type, and response to therapy. Dosage adjustments are made according to clinical guidelines and individual tolerability.

Safety data for lacosamide in pregnancy and lactation are limited. Clinicians should weigh the potential benefits against possible risks and consider alternative treatments when possible. Breastfeeding decisions should be made in consultation with a healthcare professional.

To request Lacosadel, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lacosamide belongs to the sodium channel blocker class and offers a distinct mechanism by enhancing slow inactivation, unlike many agents that target fast inactivation. It is generally well tolerated and may be preferred when patients experience side effects from other sodium‑channel blockers or need an alternative adjunctive option.

Lacosadel should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight and sources of heat to maintain stability.

Lacosadel is taken orally, usually as a tablet or capsule, with or without food. The exact administration schedule is set by the prescriber, who may start with a low dose and titrate upward based on therapeutic response and tolerability.

Serious adverse events include severe skin reactions such as Stevens‑Johnson syndrome or toxic epidermal necrolysis, cardiac conduction abnormalities like atrioventricular block, and rare cases of suicidal ideation. Patients should be monitored closely for any signs of these conditions.

Lacosadel is contraindicated in patients with known hypersensitivity to lacosamide or any of its excipients. Caution is advised for individuals with pre‑existing cardiac conduction disorders, severe hepatic impairment, or those taking interacting enzyme‑inducing medications.